Health & Biotech

WuXi XDC, a leading global Contract, Resea­­rch, Development, and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, announced it has been named the winner of the "Best Contract Development Manufacturing Organization (CDMO)" prize at the 2023 World ADC Awards. The award is a reflection of the company's continual enhancement of its industry-leading technology platform and one-stop, end-to-end services. Last year, WuXi XDC received the "Best CMO Runner-Up" award.

As the most influential award in the global ADC (antibody drug conjugate) field, the World ADC Awards recognize trailblazers that are committed to pioneering innovation, making outstanding contributions to long-term development across the ADC field, and bringing more innovative therapeutic solutions to patients around the world. WuXi XDC emerged the final winner in the "BEST CDMO" category from the nominee short list of six global CDMO companies.

Dr. Jimmy Li, CEO of WuXi XDC, commented, "We are delighted to receive this award and appreciate the recognition from our customers  and the global ADC industry by virtue of the continual strengthening of our platform, the expansion of our end-to-end services and innovation capabilities, and the impact across the ADC market. This award reflects the dedication and commitment of all employees of WuXi XDC, and highlights the company's high quality service of 100+ ADC programs globally. Looking forward, we will continue our efforts to strengthen and evolve the ADC development platform, and expand the global supply chain. By offering end-to-end services – from concept to commercial production – we are enabling the bioconjugate industry to accelerate the pace of development and bring more innovative drugs to patients worldwide."

In recent years, the ADC and broader bioconjugate market has developed rapidly with expanding prospects for improving public health. However, compared with other drugs, ADCs are characterized by high difficulty and complexity at every step – from discovery to development to commercial production. Since its inception, WuXi XDC has built an industry-leading, highly comprehensive, integrated technology platform that serves ADCs and other bioconjugates, with multidisciplinary capabilities and end-to-end production, enabling customers to accelerate pipeline development processes, reduce costs, increase research and development efficiency, and improve success rates. Driven by self-development and broad collaboration, WuXi XDC has continually strengthened its integrated, one-stop platform and, as a result, has been able to significantly reduce the ADC development timeline – taking only 13 to 15 months to go from antibody DNA sequence to Investigational New Drug (IND) filing, nearly cutting in half the traditional industry timeline.

In addition, WuXi XDC provides comprehensive one-stop GMP manufacturing services for ADCs and other bioconjugates at both the clinical and commercial stages. The Company continues to expand its end-to-end GMP manufacturing services – including monoclonal antibody intermediates, payload/linkers, and bioconjugate drug substances and drug products – demonstrating its commitment to meeting the growing demand of global customers. The recently launched new commercial facility in Wuxi, China has further increased WuXi XDC's production capacity – up to 2,000 liters for bioconjugate drug substances and 5 million vials for bioconjugate drug products. 

BD a leading global medical technology company, announced it has been named to the 100 Best Corporate Citizens List by 3BL, which recognizes outstanding environmental, social and governance (ESG) transparency and performance among 1,000 of the largest U.S. public companies. This year, BD ranked second in the health care equipment and services industry.

"As a global organization serving health systems in nearly 200 countries around the world, we are contributing meaningful, positive change on the global societal and environmental issues most relevant to our business, customers and stakeholders," said Tom Polen, chairman, CEO and president of BD. "As we've done throughout our history, we continue to build on these contributions to enable a healthier, more equitable world - from minimizing our environmental footprint to empowering an inclusive workforce, and advancing health equity and access in under-resourced areas of the world."

The 100 Best Corporate Citizens ranking is based on 184 ESG factors in seven pillars – climate change, employee relations, environment, governance, human rights, stakeholders and society, and ESG performance.

Dave Armon, CEO of 3BL said, "Achieving the transformational targets of the Paris Agreement and UN Sustainable Development Goals in this decisive decade requires all companies to truly embed ESG issues into the core of their business. The 100 Best Corporate Citizens of 2023 are answering the call by demonstrating the societal and bottom-line value of leadership and transparency around ESG topics. They are setting ambitious goals outlining robust strategies for achieving them, disclosing data to measure progress."

Spring Health, the most comprehensive global mental health solution for employers and health plans, today announced Atlas, a first-of-its-kind connected platform that empowers Human Resources teams and benefits leaders to optimize program outcomes and maximize return on investment for behavioral health.

Atlas has been designed from the ground up with the needs of time-crunched benefits leaders in mind. Atlas provides benefits leaders with a concise view of the top mental health opportunities in their population, using machine learning algorithms that make assessments across population or industry segments. These insights are intelligently paired with action plans, and users can strategize further with their Spring Health Customer Success team through unique collaboration tools or deploy resources in real-time.

Atlas solves an urgent need for better data-driven insights. HR and benefits teams are often inundated with metrics and reporting across programs and initiatives, but access to data is not enough. While 92% of employers report using benefit engagement data to make decisions, a majority say that they are challenged to draw meaningful conclusions or to take data-informed actions.

"Atlas arms HR executives with the evidence they need to make smart investments in their behavioral health programs," said Adam Chekroud, President and Co-Founder of Spring Health. "Data informs insights, insights lead to recommended actions, and actions lead to tracked outcomes that produce new data allowing for further optimization. This virtuous cycle empowers our customers with the ultimate tool for ensuring the best possible return on investment."

With Atlas, Spring Health takes program reporting beyond enrollment and engagement data; Atlas generates insights by benchmarking against organizational goals and analyzing trends. For example, a clinical insight could alert an HR leader that employees at a certain location are reporting stress at a higher rate than the rest of their population – and that this level of stress is in the top quartile among Spring Health customers. Atlas would recommend a manager training and communications strategy for this location, and then would be able to measure the decrease in stress levels at this location over time.

Zynex, Inc. an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring,  announced The Healthcare Technology Report has recognized Zynex as 23^rd in the Top 100 Healthcare Technology Companies of 2023. 2023 is the second year Zynex has been included within the report's top 100. Last year, Zynex ranked as the 33^rd company.

"We're pleased to be included in the Top 100 Healthcare Technology Companies of 2023 list for the second year in a row," said Thomas Sandgaard, CEO of Zynex. "As in years past, the list represents a wide portfolio of products and solutions. We are humbled to know that Zynex's emphasis on non-invasive patient solutions is being recognized within the life sciences community and beyond."